Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.59 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.59 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.59 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.59 |
| ▸ | HTR3B | O95264 | 1/20 | 0.59 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.59 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.59 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.59 |
| ▸ | HTR2B | P41595 | 1/20 | 0.59 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.59 |
| ▸ | HTR3A | P46098 | 1/20 | 0.59 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.59 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 0.59 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.59 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.59 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL7168823 | 0.99 | KCNH2 (0.58) | KCNH2CYP3A4CYP1A2CYP2D6HTR3E | |
| SCHEMBL19679596 | 0.85 | KCNH2 (0.63) | KCNH2CYP3A4CYP1A2CYP2D6HTR3E | |
| SCHEMBL3994326 | 0.84 | KCNH2 (0.61) | KCNH2CYP3A4CYP1A2CYP2D6HTR3E | |
| SCHEMBL4077482 | 0.82 | CYP3A4 (0.59) | KCNH2CYP3A4CYP1A2CYP2D6HTR3E | |
| Hydrochloric Acid SCHEMBL5202651 | 0.81 | CYP3A4 (0.58) | KCNH2CYP3A4CYP1A2CYP2D6HTR3E | |
| SCHEMBL13157508 | 0.79 | KCNH2 (0.55) | KCNH2CYP3A4CYP1A2CYP2D6HTR3E | |
| SCHEMBL682811 | 0.77 | CYP3A4 (0.72) | KCNH2CYP3A4CYP1A2CYP2D6HTR3E | |
| SCHEMBL13439469 | 0.77 | KCNH2 (0.62) | KCNH2CYP3A4CYP1A2CYP2D6HTR3E | |
| SCHEMBL5234561 | 0.76 | KCNH2 (0.53) | KCNH2CYP3A4CYP1A2CYP2D6HTR3E | |
| SCHEMBL19106874 | 0.76 | KCNH2 (0.66) | KCNH2CYP3A4CYP1A2CYP2D6HTR3E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7547791-B2 | One-pot process for the preparation of antiemetic agent, 1,2,3,9-tetrahydro-9-methyl-3[(2-methyl)-1H-imidazole-1-yl)methyl]-4H-carbazol-4-O | IPCA LABORATORIES LTD. (IN) | 2009-06-16 | — | — | US | disclosed |
| US-7547791-B2 | One-pot process for the preparation of antiemetic agent, 1,2,3,9-tetrahydro-9-methyl-3[(2-methyl)-1H-imidazole-1-yl)methyl]-4H-carbazol-4-O | IPCA LABORATORIES LTD. (IN) | 2009-06-16 | — | — | US | disclosed |
| US-20080009635-A1 | One-Pot Process for the Preparation of Antiemetic Agent, 1,2,3,9-Tetrahydro-9-Methyl-3[(2-Methyl)-1H-Imidazole-1-Yl)Methyl]-4H-Carbazol-4-O | IPCA LABORATORIES LIMITED (IN) | 2008-01-10 | — | — | US | disclosed |
| US-20080009635-A1 | One-Pot Process for the Preparation of Antiemetic Agent, 1,2,3,9-Tetrahydro-9-Methyl-3[(2-Methyl)-1H-Imidazole-1-Yl)Methyl]-4H-Carbazol-4-O | IPCA LABORATORIES LIMITED (IN) | 2008-01-10 | — | — | US | disclosed |
| EP-0278161-B1 | KETONE DERIVATIVES AS MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF THE WITHDRAWAL SYNDROME | GLAXO GROUP LIMITED (GB) | 1992-04-01 | — | — | EP | disclosed |
| EP-0278161-A1 | Ketone derivatives as medicaments for the treatment or prevention of the withdrawal syndrome | GLAXO GROUP LIMITED (GB) | 1988-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009635-A1 | One-Pot Process for the Preparation of Antiemetic Agent, 1,2,3,9-Tetrahydro-9-Methyl-3[(2-Methyl)-1H-Imidazole-1-Yl)Methyl]-4H-Carbazol-4-O | CRHR2, HCRTR2, HTR1D | KCNH2 513/4885CYP3A4 422/4885CYP1A2 219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.